Quotables
"Radio has no future."
Lord Kelvin, British mathematician and physicist ; 1897
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188051 | Metadherin polypeptides, encoding nucleic acids and methods of use Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as anti... | 05/29/2012 |
| 8178486 | Method for promoting hair growth A method is provided of promoting hair growth in a subject includes applying to the skin of the subject a composition including lactoferrin in an amount effective for at least one of proliferating and activating hair follicles in the hypodermis of skin of the subjec... | 05/15/2012 |
| 8173602 | Detecting CYP24 expression level as a marker for predisposition to cancer This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides m... | 05/08/2012 |
| RE43343 | Inhibitors of histone deacetylase The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and condi... | 05/01/2012 |
| 8168583 | 2-fluoronucleosides 2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: | 05/01/2012 |
| 8163691 | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling. ... | 04/24/2012 |
| 8158576 | Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, der... | 04/17/2012 |
| 8158573 | Therapeutic and diagnostic conjugates for use with multispecific antibodies Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector m... | 04/17/2012 |
| 8158575 | Agent for the prevention and treatment of sexually transmitted diseases-I Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases. ... | 04/17/2012 |
| 8158574 | Compositions and methods to prevent cancer with cupredoxins The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions m... | 04/17/2012 |
| 8153580 | Nogo receptor binding protein The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodi... | 04/10/2012 |
| 8153589 | JNK3 as a target for the treatment of angiogenesis-related diseases Provided herein are methods for treating a subject having or at risk for an angiogenesis-related disorder. The methods include administering to the subject a therapeutically effective amount of an agent that inhibits JNK3 expression, or a therapeutically effective a... | 04/10/2012 |
| 8143229 | Method for production of a transformed cell A method for incorporating a biomolecule into a cell including the steps: i) production of a complex from a biomolecule and a polymer which may be obtained by reaction of an amine monomer having at least two amine groups with an epoxide monomer having at least two e... | 03/27/2012 |
| 8138139 | Use of RGD-enriched gelatine-like proteins for inhibition of cancer metastasis The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the t... | 03/20/2012 |
| 8137918 | Sperm-specific cation channel, CatSper4, and uses therefor Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper4) are disclosed. The CatSper4 protein is shown to be specifically expressed in sperm. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and an... | 03/20/2012 |
| 8133857 | NOTCH inhibition in the treatment of atherosclerosis The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compoun... | 03/13/2012 |
| 8129329 | Natural polypeptides for oral health care The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. T... | 03/06/2012 |
| 8119589 | Modulation of CD4T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide ... | 02/21/2012 |
| 8114829 | Elastin protective polyphenolics and methods of using the same Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provid... | 02/14/2012 |
| 8114853 | Methods of treating smooth muscle cell disorders The present invention provides methods of detecting cells showing smooth muscle differentiation. The present invention further provides methods of detecting tumor cells. The present invention further provides compositions and methods for treating smooth muscle cell ... | 02/14/2012 |
| 8110557 | Gamma secretase inhibitor for treatment of herpesvirus infection This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby a... | 02/07/2012 |
| 8106000 | Colonic delivery of adsorbents Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the deliv... | 01/31/2012 |
| 8093217 | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oli... | 01/10/2012 |
| 8084413 | Urocortin-III and uses thereof A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology co... | 12/27/2011 |
| 8080515 | Method for prevention of platelet aggregation employing and RGD-enriched gelatine-like protein The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the t... | 12/20/2011 |
| 8071533 | Compositions and methods for modulating store-operated calcium entry Compositions and methods for modulating activity of store-operated calcium entry in cells or tissues are provided. The compositions comprise the P311 protein, fused to a cell-penetrating peptide and formulated for delivery to tissues and cells. This protein has been... | 12/06/2011 |
| 8071534 | Material for facilitating thermal treatments of biological tissues and method of energy targeting leading to thermal treatment of biological tissues A method includes positioning an effective amount of a thermal target material at a treatment site of a patient. The treatment site, that is, the location of the thermal target material, comprises a location adjacent to biological tissue to be treated. The thermal t... | 12/06/2011 |
| 8071532 | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ische... | 12/06/2011 |
| 8067358 | Triple-action remedy for removing toxic oils from skin with simultaneous soothing and healing Disclosed are formulae and methods for the simultaneous relief of a variety of unpleasant symptoms of poison ivy on the skin. The compositions of the present invention remove toxic urushiol, relieve itching of the skin from urushiol, and heal the dermatitis caused b... | 11/29/2011 |
| 8067356 | High fibre high calorie liquid or powdered nutritional composition The present invention relates to a nutritional composition which is liquid and shelf-stable or powdered and reconstitutable. The composition has a fiber content of more than 2.5 g/fibber per 100 ml of the composition. Furthermore, it has an energy content of 1.3-1.8... | 11/29/2011 |
| 8067357 | Annexin derivatives suitable for pretargeting in therapy and diagnosis The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept... | 11/29/2011 |
| 8058225 | Proteins for use in human and animal infections The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and va... | 11/15/2011 |
| 8058249 | Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atop... | 11/15/2011 |
| 8048844 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 11/01/2011 |
| 8030286 | Methods and means for increasing resistance to cell damage Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasi... | 10/04/2011 |
| 8026212 | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone ma... | 09/27/2011 |
| 8017574 | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone ma... | 09/13/2011 |
| 7998934 | PAI-2 conjugates for the treatment and imaging of cancer A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalen... | 08/16/2011 |
| 7998922 | Process for treating fibroses with biocompatible polymer A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): AaXxYy, in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or... | 08/16/2011 |
| 7994113 | βGBP, compositions comprising βGBP, and related methods and uses thereof The invention relates to β-galactoside binding protein (βGBP) and compositions, including pharmaceutical compositions, comprising βGBP for use in therapy and related applications. In particular, the invention relates to use of βGBP and the manufacture of medicam... | 08/09/2011 |
